Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Moderna Inc
(NQ:
MRNA
)
82.44
+1.40 (+1.73%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
4,225,210
Open
82.35
Bid (Size)
82.50 (2)
Ask (Size)
82.70 (1)
Prev. Close
81.04
Today's Range
81.25 - 84.28
52wk Range
62.55 - 170.47
Shares Outstanding
384,000,000
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
MRNA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Moderna, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
August 23, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
$100 Invested In This Stock 5 Years Ago Would Be Worth $500 Today
August 23, 2024
Via
Benzinga
Performance
YTD
-26.72%
-26.72%
1 Month
-30.25%
-30.25%
3 Month
-50.52%
-50.52%
6 Month
-14.53%
-14.53%
1 Year
-26.82%
-26.82%
More News
Read More
The Stock Market Isn't Rocking This Month But The S&P 500 Is Headed For Its Best August In 3 Years
August 23, 2024
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Europe Approves Moderna's RSV Vaccine For Adults 60 And Over
August 23, 2024
Via
Benzinga
Moderna to Host Investor Event - R&D Day and Business Updates
August 22, 2024
Via
ACCESSWIRE
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant of SARS-CoV-2
August 21, 2024
Via
ACCESSWIRE
Moderna's Options: A Look at What the Big Money is Thinking
August 21, 2024
Via
Benzinga
Moderna Receives European Commission Approval for RSV Vaccine mRESVIA(R)
August 23, 2024
Via
ACCESSWIRE
Ministry of Health, Labour and Welfare in Japan Approves Partial Change Application for Moderna's COVID-19 mRNA Vaccine Targeting SARS-COV-2 Variant JN.1
August 22, 2024
Via
ACCESSWIRE
Nasdaq 100 Slumps 1.6% As Traders Turn Cautious Ahead Of Powell's Jackson Hole Address
August 22, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
FDA Approves Updated COVID Vaccines From Pfizer And Moderna, But Leaves Out Novavax's Shot
August 22, 2024
Via
Benzinga
Exposures
COVID-19
Product Safety
Stocks Move Lower As Rate Cut Enthusiasm Fades
August 22, 2024
Via
Talk Markets
Topics
Economy
Exposures
Interest Rates
MRNA Investors Have Opportunity to Lead Moderna, Inc. Securities Fraud Lawsuit with the Schall Law Firm
August 21, 2024
From
Schall Law
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, PDD Holdings, Extreme Networks, and Sprinklr and Encourages Investors to Contact the Firm
August 20, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
MNRA STOCK NEWS: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Moderna, Inc. Class Action
August 20, 2024
From
Robbins LLP
Via
GlobeNewswire
S&P 500, Nasdaq 100 Snap 8-Day Winning Streak: What Triggered Wall Street's Setback On Tuesday?
August 20, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
GeoVax Labs: Is This Micro-Cap Biotech Stock a Boom or a Bust?
August 20, 2024
Via
MarketBeat
Exposures
COVID-19
S&P 500, Nasdaq 100 Extend 8-Session Winning Streak As Wall Street Jitters 'Go Poof': Monday's Key Stock Movers
August 19, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Novavax Stock Rocketed This Year, But Challenges Persist. Is It A Buy Or A Sell?
August 19, 2024
Via
Investor's Business Daily
Rosen Law Firm Urges Moderna, Inc. (NASDAQ: MRNA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
August 19, 2024
From
The Rosen Law Firm, P.A.
Via
Business Wire
MODERNA, INC. (NASDAQ: MRNA) INVESTOR ALERT: Investors With Large Losses in Moderna, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
August 19, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch
August 19, 2024
Via
Benzinga
Topics
ETFs
Exposures
COVID-19
Product Safety
Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
August 19, 2024
Via
MarketBeat
Exposures
COVID-19
Product Safety
Pfizer and BioNTech's Combo Shot Missed the Mark. Is It Time to Sell?
August 19, 2024
Via
The Motley Fool
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna and Sprinklr and Encourages Investors to Contact the Firm
August 18, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.